References of "Krzesinski, Jean-Marie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffect of candesartan cilexetil and angiotensin-converting enzyme inhibitor therapy on treatment adherence in hypertension
Krzesinski, Jean-Marie ULg; Lins, R.; Vandenhoven, G. et al

in Journal of Hypertension (2001), 19

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailComparison of the candesartan cilexetil and angiotensin-converting enzyme inhibitor therapy in mild to moderate hypertension
Krzesinski, Jean-Marie ULg; Lins, R.; Vandenhoven, G. et al

in Journal of hypertension (2001)

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailComparison of the antihypertensive efficacy and tolerability of candesartan cilexetil and angiotensin-converting enzyme inhibitor therapy in primary hypertension: the champion study
Lins, R.; Krzesinski, Jean-Marie ULg; Vandenhoven, G. et al

in American Journal of Hypertension : Journal of the American Society of Hypertension (2001), 4

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailQualité du contrôle de la pression artérielle des patients hémodialysés en Belgique francophone
Collart, F.; Krzesinski, Jean-Marie ULg

in Archives des Maladies du Coeur et des Vaisseaux (2001), 95

Detailed reference viewed: 8 (0 ULg)
Full Text
See detailAmbulatory blood pressure monitoring : a tool or a toy?
Rorive, Georges ULg; Krzesinski, Jean-Marie ULg

Scientific conference (2000, November 04)

Detailed reference viewed: 8 (0 ULg)
See detailL'hypertension artérielle systolique isolée
Krzesinski, Jean-Marie ULg

Conference (2000, October 18)

Detailed reference viewed: 14 (0 ULg)
Full Text
Peer Reviewed
See detailObésité et hypertension artérielle: de la physiopathologie au traitement
Geronooz, Isabelle; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2000), 55(10), 921-928

Obesity constitutes a problem of major concern in our industrialized countries. Overweight is frequently associated with hypertension (50% of hypertensive subjects are obese and the prevalence of ... [more ▼]

Obesity constitutes a problem of major concern in our industrialized countries. Overweight is frequently associated with hypertension (50% of hypertensive subjects are obese and the prevalence of hypertension in obese patients is twice that of the normal population). Both pathologies are major cardiovascular risk factors. This review aims at a better understanding of the relationship between hypertension and overweight and at giving to the clinicians simple and consistent guidelines to treat these two medical entities. [less ▲]

Detailed reference viewed: 946 (1 ULg)
See detailEtude INSIGHT – présentation des résultats
Krzesinski, Jean-Marie ULg

Conference (2000, September 24)

Detailed reference viewed: 7 (3 ULg)
See detailHypertension artérielle et organes-cibles
Krzesinski, Jean-Marie ULg

Conference (2000, September 21)

Detailed reference viewed: 4 (0 ULg)
See detailEtudes IDNT-RENAAL
Krzesinski, Jean-Marie ULg

Conference (2000, September 20)

Detailed reference viewed: 13 (0 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Comment je traite ... un trouble de la kaliémie
Neven, Ingrid; Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (2000), 55(1), 4-7

The treatment of dyskalemia must be primarily etiological and later symptomatic. When moderate but significant hypokalemia exists (K < 3 mmol/l or 3.5 mmol/l with cardiac disease), oral K supplements must ... [more ▼]

The treatment of dyskalemia must be primarily etiological and later symptomatic. When moderate but significant hypokalemia exists (K < 3 mmol/l or 3.5 mmol/l with cardiac disease), oral K supplements must be given. The intravenous route must be reserved for emergency or impossible oral administration. Acute and severe hyperkalemia (K > 7 mmol/l) must be first corrected by different intravenous measures with secondary oral intervention. In chronic and/or moderate hyperkalemia (K > 5.5 mmol/l), the oral route for treatment is prefered. In any case, the research of the cause (mainly drug induced) is fundamental. [less ▲]

Detailed reference viewed: 194 (15 ULg)
Peer Reviewed
See detailIron monitoring under vitamin C therapy in hemodialysed patients treated with erythropoietin
Bovy, Christophe ULg; Dubois, Bernard ULg; Weekers, Laurent ULg et al

in Nephrology Dialysis Transplantation (2000), 15(9), 156

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailMesure de la pression artérielle en dehors du cabinet médical: intérêts et limites
Krzesinski, Jean-Marie ULg; Saint-Remy, Annie ULg

in Revue Médecine Générale (2000), 176

Standardized blood pressure self measurement with approved devices allows the patient's involvement in the diagnosis and provides information on various parameters.

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailLes sartans face aux inhibiteurs de l'enzyme de conversion de l'angiotensine en présence d'une hypertension artérielle
Krzesinski, Jean-Marie ULg; Sternon, J.

in Revue Médicale de Bruxelles (2000), 21(3), 170-177

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the wrist cuff oscillometric blood pressure measurement in clinical practice
Saint-Remy, Annie ULg; Moonen, Martial; Krzesinski, Jean-Marie ULg et al

in Journal of Hypertension (Supplement) (2000), 18(suppl 2), 55

Detailed reference viewed: 15 (3 ULg)
Full Text
Peer Reviewed
See detailPharma clinics. Le médicament du mois. La lercanidipine (Zanidip)
Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (1999), 54(10), 832-834

Lercanidipine (Zanidip) is a new calcium antagonist belonging to the dihydropyridine family suitable for the first-line treatment of hypertension. This molecule displays a high specificity and selectivity ... [more ▼]

Lercanidipine (Zanidip) is a new calcium antagonist belonging to the dihydropyridine family suitable for the first-line treatment of hypertension. This molecule displays a high specificity and selectivity for vascular smooth muscle cells and has, in spite of a short plasma half-life, a long duration of action due to its liposolubility. The usual and once a day dose to treat high blood pressure of any grade is 10 mg, which if needed could be increased to 20 mg once a day. It has a gradual onset of effect on blood pressure, thus leading to a good tolerability and hopefully a better compliance in the treatment of hypertension. No adaptation of the dose is needed in older patients or in patients with moderate renal or liver impairment. [less ▲]

Detailed reference viewed: 275 (0 ULg)
Full Text
Peer Reviewed
See detailHypertension et grossesse
Krzesinski, Jean-Marie ULg

in Revue Médicale de Liège (1999), 54(5), 415-423

High blood pressure during pregnancy (BP > or = 140/90 mmHg) is sometimes already noted before conception, with usually a good prognosis (although it could predispose to preeclampsia). alpha-methyldopa is ... [more ▼]

High blood pressure during pregnancy (BP > or = 140/90 mmHg) is sometimes already noted before conception, with usually a good prognosis (although it could predispose to preeclampsia). alpha-methyldopa is the best treatment when needed (agents blocking the renin angiotensin system are not recommended). Preeclampsia, a form of hypertension noted after 20 weeks of gestation with proteinuria is a more serious condition (BP > or = 140/90 mmHg or increase in BP from the 1st trimester > or = 25/15 mmHg). It is generated by placental ischemia and creates maternal endothelial lesions which in turn decrease the blood flow to placenta leading to maternal and fetal syndromes. Hospitalisation is mandatory. No measure other than delivery is known to attenuate or reverse its progression. Treating hypertension during pregnancy (when blood pressure > or = 170/110 mmHg) aims at preventing maternal risk (stroke or eclampsia) but has few effect on foetal lesions. Prevention of this syndrome, which represents the first secondary cause of hypertension, is until now disappointing. [less ▲]

Detailed reference viewed: 261 (2 ULg)